Accreditation The American Medical Directors Association (AMDA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: The American Medical Directors Association designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AMDCP Credit Designation: This session has been approved for a total of management 1.5 credit hours toward certification as a Certified Medical Director in Long Term Care (CMD).
Session Description: This session will provide an overview of the increasing incidence and severity of C. difficile infection in the United States and the impact of C. difficile infection on residents in long term care. The presenter will address the significant diagnostic and treatment challenges of C. difficile and highlight the importance of infection control and prevention in the long term care setting.
Assess the changing epidemiology of C. difficile infection.
Describe the impact of C. difficile infection on hospitalized patients and residents in long term care.
Identify the important characteristics of the organism of C. difficile that create a need for distinct infection control policies.
Speakers(s): Laurie R. Archbald-Pannone, MD
Disclosure(s): Laurie R. Archbald-Pannone, MD - TechLab.: Research grant awarded April 2011-October 2011
References(s): 1. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007 Aug 1;45(3):302-7. 2. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med ; N Engl J Med. 2002 January 31;346(5):334-9. 3. Bartlett JG. Narrative review: The new epidemic of clostridium difficile-associated enteric disease. Ann Intern Med. 2006 November 21;145(10):758-64. 4. Bartlett J, Gerding D. Clinical recognition and diagnosis of clostridium difficile infection. Clinical Infectious Diseases. 2008 01/15;46:S12-8. 5. Zilberberg MD. Clostridium difficile-related hospitalizations among US adults, 2006. Emerging Infectious Diseases. 2009;January. 6. Bartlett JG. Antibiotic-associated colitis. Dis Mon. 1984;30:1-54. 7. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control and Hospital Epidemiology. 2010;31(5):431-55. 8. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nature Reviews Microbiology. 2009 July 2009;7:526-36. 9. CDC. Severe clostridium difficile-associated disease in populations previously at low risk--four states. MMWR. 2006;54(47):1201-5. 10. Zilberberg MD, Tillotson GS, McDonald LC. Clostridium difficile infections among hospitalized children, united states, 1997-2006. Emerg Infect Dis [serial on the Internet]. 2010 March 2010. 11. Baker SS, Faden H, Sayej W, et al. Increasing incidence of community-associated atypical clostridium difficile disease in children. Clin Pediatr 11 February 2010. 12. Redelings MD, Sorvillo F, Mascola L. Increase in clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis. 2007;September. 13. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of clostridium difficile associated with outbreaks of severe disease in North America and Europe. The Lancet. 2005;366(9491):1079-84. 14. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Qu